Swedish Orphan Biovitrum AB (Sobi) operates a specialized biopharmaceutical business model focused on rare diseases with high unmet medical need. The company organizes its commercial operations into three primary business areas: Haematology, Immunology, and Specialty Care. Haematology represents its largest revenue generator, encompassing treatments for rare blood disorders including recombinant coagulation factor therapies Elocta and Alprolix, next-generation haemophilia A treatment Altuvoct, thrombopoietin receptor agonist Doptelet (avatrombopag), and JAK2/IRAK1 inhibitor Vonjo (pacritinib). Immunology includes Kineret (interleukin-1 receptor antagonist), Gamifant (emapalumab for primary hemophagocytic lymphohistiocytosis), and royalty revenues from respiratory syncytial virus preventive therapy Beyfortus. Specialty Care includes treatments for rare metabolic and genetic disorders, such as Orfadin (nitisinone). Sobi derives revenue primarily through direct commercial product sales and royalties, complemented by strategic development and co-promotion collaborations with pharmaceutical partners such as Sanofi. Geographically, Europe and North America represent its primary markets, supplemented by growing operations in Asia, the Middle East, and Australia.
